Quick Answer
Transcode Therapeutics, Inc. reported Operating Income Loss of -$15.66 million for the year ending 2024.
- Transcode Therapeutics, Inc. showed an increase of +19.4% in Operating Income Loss from 2023 to 2024.
- This data is from Transcode Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$91.6 thousand | Q3 2020: -$239.5 thousand | Q1 2021: -$449.5 thousand | Q2 2021: -$355.5 thousand | Q3 2021: -$2.36 million | Q1 2022: -$3.48 million | Q2 2022: -$4.71 million | Q3 2022: -$4.95 million | Q1 2023: -$4.89 million | Q2 2023: -$5.12 million | Q3 2023: -$5.31 million | Q1 2024: -$3.29 million | Q2 2024: -$5.11 million | Q3 2024: -$2.17 million | Q1 2025: -$3.17 million | Q2 2025: -$4.22 million | Q3 2025: -$4.56 million.
- Over the full 5 years of available data (2020 to 2024), Transcode Therapeutics, Inc.'s Operating Income Loss has declined by 2,055.3%.
- Historical annual values: Fiscal year 2024: -$15.66 million | Fiscal year 2023: -$19.42 million | Fiscal year 2022: -$18.63 million | Fiscal year 2021: -$6.15 million | Fiscal year 2020: -$726.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: